Bio-Techne (TECH) Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TECH shares.
View TECH analyst ratings or view top-rated stocks.

9 brokerages have issued 1 year price objectives for Bio-Techne's shares. Their TECH share price forecasts range from $86.00 to $120.00. On average, they anticipate the company's stock price to reach $101.58 in the next year. This suggests a possible upside of 46.5% from the stock's current price.
View analysts price targets for TECH or view top-rated stocks among Wall Street analysts.

Bio-Techne's stock was trading at $82.88 at the beginning of 2023. Since then, TECH stock has decreased by 16.3% and is now trading at $69.35.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our TECH earnings forecast.

Bio-Techne Co. (NASDAQ:TECH) posted its quarterly earnings results on Tuesday, August, 8th. The biotechnology company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.49 by $0.07. The biotechnology company earned $301.32 million during the quarter, compared to the consensus estimate of $304.71 million. Bio-Techne had a net margin of 25.10% and a trailing twelve-month return on equity of 15.47%.

Bio-Techne declared a quarterly dividend on Tuesday, August 8th. Shareholders of record on Friday, August 18th will be paid a dividend of $0.08 per share on Friday, September 1st. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.46%. The ex-dividend date is Thursday, August 17th.
Read our dividend analysis for TECH.

ETFs with the largest weight of Bio-Techne (NASDAQ:TECH) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), American Century Mid Cap Growth Impact (MID), First Trust NYSE Arca Biotechnology Index Fund (FBT), VanEck Biotech ETF (BBH), BlackRock Future Innovators ETF (BFTR), Putnam BioRevolution ETF (SYNB), Fidelity Disruptive Medicine ETF (FMED) and Harbor Health Care ETF (MEDI).

Bio-Techne (NASDAQ:TECH) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.45%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 18.16%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TECH will have a dividend payout ratio of 15.53% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for TECH.

Bio-Techne's stock split before market open on Wednesday, November 30th 2022. The 4-1 split was announced on Tuesday, November 1st 2022. The newly issued shares were distributed to shareholders after the market closes on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

95 employees have rated Bio-Techne Chief Executive Officer Charles Kummeth on Glassdoor.com. Charles Kummeth has an approval rating of 73% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and Boeing (BA).

Bio-Techne trades on the NASDAQ under the ticker symbol "TECH."

Bio-Techne's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.74%), State Street Corp (4.07%), Geode Capital Management LLC (2.25%), Brown Capital Management LLC (2.01%), William Blair Investment Management LLC (1.47%) and Ownership Capital B.V. (1.45%). Insiders that own company stock include Alpna Seth, Brenda S Furlow, Brenda S Furlow, Charles R Kummeth, Charles R Kummeth, Glenn Hedde, James Hippel, John L Higgins, Kim Kelderman, Norman David Eansor, Robert V Baumgartner and Roeland Nusse.
View institutional ownership trends.

Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TECH stock can currently be purchased for approximately $69.35.

Bio-Techne (NASDAQ:TECH) has a market capitalization of $10.97 billion and generates $1.14 billion in revenue each year. The biotechnology company earns $285.26 million in net income (profit) each year or $1.7625 on an earnings per share basis.

The company employs 3,050 workers across the globe.

Bio-Techne's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The official website for the company is www.bio-techne.com. The biotechnology company can be reached via phone at (612) 379-8854, via email at ir@bio-techne.com, or via fax at 612-656-4400.